PHILADELPHIA – Zhe Lu, M.D., Ph.D., Professor of Physiology at the University of Pennsylvania School of Medicine, was selected to be a Howard Hughes Medical Institute (HHMI) investigator last week. HHMI honors and supports some of the nation's most creative biomedical scientists by giving them the opportunity to tackle their most ambitious and risky research projects. Dr. Lu is one of the 56 biomedical scientists chosen. HHMI has committed more than $600 million to support these newly selected investigators.
Dr. Lu is truly humbled by the award, crediting the honor largely to the members of his lab, and is extremely grateful to the supportive environment created by the colleagues in his department and at other institutions throughout his career. “I would never be able to do the research I do today without their support and especially the guidance of such mentors as Professor Roderick MacKinnon at Harvard Medical School [now a HHMI investigator at Rockefeller University], and Professors Paul DeWeer and Clay Armstrong in the Department of Physiology at Penn.” He is delighted that the support from HHMI will enable his lab to develop therapeutic strategies to combat certain diseases that currently lack effective treatment, and to pursue the answers to some fundamental biological questions.
“These 56 scientists will bring new and innovative ways of thinking about biology to the HHMI community,” said Thomas R. Cech, president of HHMI. “They are poised to advance scientific knowledge dramatically in the coming years, and we are committed to providing them with the freedom and flexibility to do so.”
Lu works on ion channels, tunnels in a cell’s membrane that allow ions – such as potassium or chloride – to enter or exit. He started formulating his ideas about ion channels when he was a postdoctoral fellow in the lab of Dr. Roderick MacKinnon at Harvard University. For nearly a decade he has been exploring the inner workings of ion channels and how this knowledge sheds new light on the pathology of such diseases as cystic fibrosis and MRSA.
For example, last year his lab discovered that an enzyme produced by lung-infecting bacteria further shuts down the channel protein that is defective in cystic fibrosis (CF) patients. Disruption of the function of this channel causes thick mucus to buildup inside the lungs of CF patients. The effect of the bacterial toxin now helps to explain why the severity of CF symptoms did not match the type of genetic mutation. This finding suggests a new therapeutic target for treating lung disease in some CF patients.
More recently, Lu and colleagues demonstrated that a bacterial toxin, sphingomyelinase C, from the common bacterium Staphylococcus aureus disables the controlmechanism of the ion channel in immune-cell membranes. Shutting down ion channels has long been known to suppress the immune response, and the bacteria may use the toxin to neutralize host defenses against bacteria. Their finding suggests that identifying inhibitors against the toxin may provide a new way to combat S. aureus infections. One strain of S. aureus is the much-talked-about MRSA, or methycillin-resistant S. aureus. Specific inhibitors of the toxin may expand the choice of therapies for treating MRSA and other resistant S. aureus infections.
Lu received his MD from Beijing Medical University and his PhD in physiology from the University of Wisconsin-Madison.
HHMI chose the finalists from among 1,070 applications submitted in a nationwide competition, which was announced in 2007. Researchers with 4 to 10 years of experience as faculty members at more than 200 institutions were eligible to apply. To evaluate the applications, HHMI assembled review panels of distinguished biomedical scientists.
This is the first time that HHMI opened up a general competition to the direct application process. Prior institutional approval was not part of the process, as it had been for previous HHMI investigator competitions. It is an approach HHMI used for the first time in November 2006, for a smaller, more focused competition that led to the appointment of 15 physician scientists. HHMI changed the way it selects investigators to ensure that candidates are drawn from a broader and deeper pool of scientists.
PENN Medicine is a $3.5 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.
Penn's School of Medicine is currently ranked #4 in the nation in U.S.News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals — its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s “Honor Roll” hospitals by U.S.News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center — a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community.